PR Newswire
NORTH CHICAGO, Ill., Dec. 6, 2022
-- Fifteen abstracts underscore AbbVie's commitment to people living with migraine
-- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study on neck pain with headache in people with and without migraine
-- Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine in Europe will also be presented
NORTH CHICAGO, Ill., Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress 2022 (EHC 2022) taking place in Vienna, Austria, December 7-10. A total of 15 abstracts will cover a wide range of studies across AbbVie's migraine portfolio, including data on onabotulinumtoxinA and atogepant.
"AbbVie is a committed leader in migraine with extensive history of migraine research. We work alongside patients, care partners and clinicians to provide solutions for the often-unrelenting burden of migraine," said Mudra Kapoor, M.D., vice president, neuroscience, global medical affairs, AbbVie. "Our research presented at this year's EHC 2022 reinforces our commitment to making an impact in the migraine community and builds upon our mission to provide therapies for people living with migraine."
At the meeting, researchers will present late-breaking data from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study, evaluating the frequency and burden of neck pain with headache among people with and without migraine.
AbbVie will also present the Phase 3 PROGRESS trial, including results from patients with chronic migraine living in Europe. In addition to the data presented, AbbVie will host a Medical Symposium on Friday, December 9 from 2:15-3:15 p.m. Central European Time (CET) titled "A Paradigm Shift in Migraine Management."
AbbVie abstracts presented at the EHC 2022 are outlined below.
Key AbbVie Abstracts at EHC 2022 ARIVA.DE Börsen-GeflüsterWerbung Weiter aufwärts?
Vontobel
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: VD0XDE,VM6U8Z,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse | |||||||||||||||||
Abstract Title | Abstract Details & Time Zone: | ||||||||||||||||
Atogepant | |||||||||||||||||
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: | Friday, December 9 16:15 – 16:20 pm CET ePoster | ||||||||||||||||
Atogepant for the Preventive Treatment of Chronic Migraine: Results from | Friday, December 9 15:30 – 15:35 pm CET ePoster | ||||||||||||||||
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post | Friday, December 9 15:40 – 15:45 pm CET ePoster | ||||||||||||||||
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific | Friday, December 9 16:55 – 17:00 pm CET ePoster | ||||||||||||||||
Subsequent Response to Atogepant in Individuals with Episodic Migraine | Friday, December 9 16:05 – 16:10 pm CET ePoster | ||||||||||||||||
Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label | Friday, December 9 15:45 – 15:50 pm CET ePoster | ||||||||||||||||
Effect of Atogepant on the Activity Impairment in Migraine–Diary and | Friday, December 9 16:05 – 16:10 pm CET ePoster | ||||||||||||||||
Treatment Responder Rates of Oral Atogepant for the Preventive | Friday, December 9 16:40 – 16:45 pm CET ePoster | ||||||||||||||||
Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and | Friday, December 9 16:00 – 16:05 pm CET ePoster | ||||||||||||||||
Safety and Tolerability of Atogepant: A Post Hoc Analysis of | Friday, December 9 15:55 – 16:00 pm CET ePoster | ||||||||||||||||
Migraine Disease | | ||||||||||||||||
Characterizing Neck Pain with Headache in People with and without Migraine:
| Friday, December 9 15:35 – 15:40 pm CET Late-Breaker ePoster | ||||||||||||||||
Characterizing Gaps in Preventive Treatment of Migraine: Global Results from | Friday, December 9 15:50 – 15:55 pm CET ePoster | ||||||||||||||||
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: | Friday, December 9 16:45 – 16:50 pm CET ePoster | ||||||||||||||||
OnabotulinumtoxinA | | ||||||||||||||||
Evaluation of PREEMPT Fixed-dose, Fixed-site and Follow the Pain | Friday, December 9 15:30 – 15:35 pm CET ePoster | ||||||||||||||||
Real-World Persistence and Costs Among Patients with Chronic Migraine | Friday, December 9 16:25 – 16:30 pm CET ePoster |
The EHC 2022 will be a hybrid meeting taking place in-person and virtually. The full program for the congress can be found here.
About Atogepant
Atogepant is an orally administered, CGRP receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks and selective CGRP receptor antagonists confer clinical benefit in migraine. AbbVie has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The use of atogepant in migraine is not approved in the United Kingdom or European Union and its safety and efficacy have not been evaluated.
U.S. Indications and Important Safety Information about QULIPTA™ (atogepant)
QULIPTA is a prescription medicine used for the preventive treatment of episodic migraine in adults.
IMPORTANT SAFETY INFORMATION
Before taking QULIPTATM (atogepant) tablets, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines.
The most common side effects of QULIPTA are nausea, constipation, and tiredness. These are not all the possible side effects of QULIPTA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
Please see full Prescribing Information.
Globally, prescribing information varies; refer to the individual country product label for complete information.
About BOTOX®
BOTOX® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Today, BOTOX® is FDA-approved for 12 therapeutic indications, including chronic migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults and in pediatric patients five years of age and older, cervical dystonia, adult and pediatric spasticity, and severe underarm sweating (axillary hyperhidrosis). Botulinum toxin units are not interchangeable from one product to another; doses recommended in Allergan Units are different from other botulinum toxin preparations.
U.S. Indications and Important Safety Information about BOTOX® (onabotulinumtoxinA)
INDICATIONS
BOTOX® (onabotulinumtoxinA) is a prescription medicine that is injected into muscles and used:
BOTOX is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.
It is not known whether BOTOX is safe and effective to prevent headaches in patients with migraine who have 14 or fewer headache days each month (episodic migraine).
BOTOX has not been shown to help people perform task-specific functions with their upper limbs or increase movement in joints that are permanently fixed in position by stiff muscles. It is not known whether BOTOX is safe and effective for severe sweating anywhere other than your armpits.
IMPORTANT SAFETY INFORMATION
BOTOX may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX:
There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX has been used at the recommended dose to treat chronic migraine, severe underarm sweating, blepharospasm, or strabismus.
BOTOX may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Do not receive BOTOX if you are allergic to any of the ingredients in BOTOX (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
Do not receive BOTOX for the treatment of urinary incontinence if you have a urinary tract infection (UTI) or cannot empty your bladder on your own and are not routinely catheterizing. Due to the risk of urinary retention (difficulty fully emptying the bladder), only patients who are willing and able to initiate catheterization posttreatment, if required, should be considered for treatment.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.